Triple-negative breast cancer (TNBC), which is characterized by negativity for Estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor type (HER) 2, is a high-risk breast cancer that lacks specific targets for treatment selection [1–8]. The gene discussed is ESR1; the disease is breast carcinoma.